These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [A fairer comparison between carvedilol and metoprolol is still to be done]. Johnsson G; Aberg J Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018 [No Abstract] [Full Text] [Related]
44. Role of carvedilol in atrial fibrillation: insights from clinical trials. Gheorghiade M; Lukas MA Am J Cardiol; 2004 May; 93(9A):53B-7B. PubMed ID: 15144939 [TBL] [Abstract][Full Text] [Related]
45. [Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Results of a randomised study]. Latini R Ital Heart J Suppl; 2001 Jun; 2(6):692-3. PubMed ID: 11460849 [No Abstract] [Full Text] [Related]
49. Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. Horenstein MS; Ross RD; Singh TP; Epstein ML Pediatr Cardiol; 2002; 23(1):100-2. PubMed ID: 11922497 [TBL] [Abstract][Full Text] [Related]
50. Peak exercise responses in heart failure: back to basics. Cohen-Solal A; Beauvais F; Tan LB Eur Heart J; 2009 Dec; 30(24):2962-4. PubMed ID: 19561029 [No Abstract] [Full Text] [Related]
51. Letter to editor: Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. Sarli B; Celik T; Kaya MG Int J Cardiol; 2013 Oct; 168(3):3134-5. PubMed ID: 23628294 [No Abstract] [Full Text] [Related]
52. Multiple action agents in cardiovascular therapy. Satellite symposium to the 5th European Meeting on Hypertension. Milan, Italy, June 11, 1991. J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S1-146. PubMed ID: 1378132 [No Abstract] [Full Text] [Related]
53. A case of plastic bronchitis presenting 9 years after Fontan. Zaccagni HJ; Kirchner L; Brownlee J; Bloom K Pediatr Cardiol; 2008 Jan; 29(1):157-9. PubMed ID: 17929079 [TBL] [Abstract][Full Text] [Related]
54. Letter by Rosner et al regarding article, "When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure". Rosner GF; Garan AR; Uriel N Circulation; 2013 Jan; 127(4):e431. PubMed ID: 23357667 [No Abstract] [Full Text] [Related]
55. [Clinical and hemodynamic efficiency of dilatrend treatment in patients with dilatation cardiomyopathy]. Dzhaniashvili MI; Chanturiia NG; Panchulidze GA Georgian Med News; 2005 Dec; (129):60-3. PubMed ID: 16444033 [TBL] [Abstract][Full Text] [Related]
56. Carvedilol. A wide therapeutic potential in cardiovascular syndromes. Proceedings of a satellite symposium organized by the International Institute for Therapeutic Research (ICIT). Scheveningen, The Netherlands, August 23, 1991. Cardiology; 1993; 82 Suppl 3():1-58. PubMed ID: 8221744 [No Abstract] [Full Text] [Related]
57. Heart failure. Unfinished business--a possible role for vasodilators. Poole-Wilson PA Int J Cardiol; 1993 Jun; 40(1):1-6. PubMed ID: 8349361 [No Abstract] [Full Text] [Related]
58. The concomitant use of suloctidil and a long-acting oral anticoagulant. Verhaeghe R; Vanhoof A Acta Clin Belg; 1977; 32(1):36-8. PubMed ID: 331824 [No Abstract] [Full Text] [Related]
59. Carvedilol use in heart failure. Neal CP; Kendrach MG Ann Pharmacother; 1998 Mar; 32(3):376-81. PubMed ID: 9533068 [No Abstract] [Full Text] [Related]